US 12,358,979 B2
Antibodies that bind interleukin 13 and methods of use
Hussam H. Shaheen, Waltham, MA (US); Kenneth Evan Thompson, Waltham, MA (US); Peter Harwin, Waltham, MA (US); and Tomas Kiselak, Waltham, MA (US)
Assigned to Apogee Therapeutics, Inc., Waltham, MA (US)
Filed by Apogee Therapeutics, Inc., Waltham, MA (US)
Filed on Dec. 13, 2024, as Appl. No. 18/979,795.
Application 18/979,795 is a continuation of application No. PCT/US2023/068621, filed on Jun. 16, 2023.
Claims priority of provisional application 63/469,167, filed on May 26, 2023.
Claims priority of provisional application 63/462,822, filed on Apr. 28, 2023.
Claims priority of provisional application 63/353,367, filed on Jun. 17, 2022.
Prior Publication US 2025/0129150 A1, Apr. 24, 2025
Int. Cl. C07K 16/24 (2006.01); A61K 39/00 (2006.01)
CPC C07K 16/244 (2013.01) [A61K 2039/505 (2013.01); C07K 2317/24 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01); C07K 2317/94 (2013.01)] 21 Claims
 
1. An isolated antibody that binds Interleukin 13 (IL-13), wherein the antibody comprises
a heavy chain variable region sequence set forth in SEQ ID NO: 3 and
a light chain variable region sequence set forth in SEQ ID NO: 39, and
wherein the antibody comprises a human IgG1 Fc region with LALA and/or YTE mutations.